Literature DB >> 30243657

Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations.

Josef Symon S Concha1, Aikaterini Patsatsi1, Ann Marshak-Rothstein2, Ming-Lin Liu1, Animesh A Sinha3, Lela A Lee4, Joseph F Merola5, Ali Jabbari6, Johann E Gudjonsson7, François Chasset8, Paul Jarrett9, Benjamin Chong10, Lisa Arkin11, Anthony P Fernandez12, Marzia Caproni13, Steven A Greenberg14, Hee Joo Kim15, David R Pearson1, Alisa Femia16, Ruth Ann Vleugels5, David Fiorentino17, Manabu Fujimoto18, Joerg Wenzel19, Victoria P Werth20.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30243657      PMCID： PMC6394859          DOI： 10.1016/j.jid.2018.08.017

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  47 in total

1.  Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.

Authors:  Alisa N Femia; A Brooke Eastham; Christina Lam; Joseph F Merola; Abrar A Qureshi; Ruth Ann Vleugels
Journal:  J Am Acad Dermatol       Date:  2013-10       Impact factor: 11.527

2.  Itch in dermatomyositis: the role of increased skin interleukin-31.

Authors:  H J Kim; M Zeidi; D Bonciani; S M Pena; J Tiao; S Sahu; V P Werth
Journal:  Br J Dermatol       Date:  2018-06-21       Impact factor: 9.302

3.  Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life.

Authors:  E S Robinson; R Feng; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2014-11-30       Impact factor: 9.302

4.  Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy.

Authors:  Mohammad Salajegheh; Sek Won Kong; Jack L Pinkus; Ronan J Walsh; Anne Liao; Remedios Nazareno; Anthony A Amato; Bryan Krastins; Chris Morehouse; Brandon W Higgs; Bahija Jallal; Yihong Yao; David A Sarracino; Kenneth C Parker; Steven A Greenberg
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

Review 5.  Recent advances in dermatomyositis-specific autoantibodies.

Authors:  Manabu Fujimoto; Rei Watanabe; Yosuke Ishitsuka; Naoko Okiyama
Journal:  Curr Opin Rheumatol       Date:  2016-11       Impact factor: 5.006

6.  The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.

Authors:  David Fiorentino; Lorinda Chung; Jeff Zwerner; Antony Rosen; Livia Casciola-Rosen
Journal:  J Am Acad Dermatol       Date:  2011-04-29       Impact factor: 11.527

7.  Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus.

Authors:  Benedikt Scholtissek; Sabine Zahn; Judith Maier; Sophie Klaeschen; Christine Braegelmann; Michael Hoelzel; Thomas Bieber; Winfried Barchet; Joerg Wenzel
Journal:  J Invest Dermatol       Date:  2017-03-27       Impact factor: 8.551

8.  Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Authors:  Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

9.  Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.

Authors:  Josefina Cortés-Hernández; Gabriela Ávila; Miquel Vilardell-Tarrés; Josep Ordi-Ros
Journal:  Arthritis Res Ther       Date:  2012-12-07       Impact factor: 5.156

10.  Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis.

Authors:  Ali Jabbari; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Juana Gonzalez; Inna Cueto; Andrew G Franks; James G Krueger
Journal:  J Invest Dermatol       Date:  2013-06-14       Impact factor: 8.551
View more
  5 in total

1.  A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.

Authors:  V P Werth; J T Merrill
Journal:  Br J Dermatol       Date:  2019-05       Impact factor: 9.302

Review 2.  Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.

Authors:  Kristen L Chen; Rebecca L Krain; Victoria P Werth
Journal:  F1000Res       Date:  2019-03-25

Review 3.  The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review.

Authors:  Srita Chakka; Rebecca L Krain; Josef Symon S Concha; Benjamin F Chong; Joseph F Merola; Victoria P Werth
Journal:  Ann Transl Med       Date:  2021-03

Review 4.  Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis.

Authors:  Victoria P Werth; Anca D Askanase; Ingrid E Lundberg
Journal:  Int J Womens Dermatol       Date:  2021-09-24

5.  Lymphedema of the Arm after COVID-19 Vaccination in a Patient with Hidden Breast Cancer and Paraneoplastic Dermatomyositis.

Authors:  Cristina Aimo; Elena Biancamaria Mariotti; Alberto Corrà; Lavinia Quintarelli; Beatrice Bianchi; Alice Verdelli; Valentina Ruffo di Calabria; Marzia Caproni
Journal:  Vaccines (Basel)       Date:  2022-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.